AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
CEO and Founder Gunjan Bhardwaj, PhD On Driving Innovation and Ensuring Success
Gunjan Bhardwaj is the Founder and CEO of the Innoplexus group. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation.
He has led projects in strategy, analytics and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry.
Innoplexus is at the forefront of decision-making technology as the company works in data aggregation to provide to researchers, pharmaceutical companies, hospitals, and more. CEO and Founder Gunjan Bhardwaj, PhD, focuses his effort on managing exploratory and exploitative innovation. He recognizes the issue of security and data sharing in the EU and Innoplexus has taken advantage of the opportunity to make as much life science data available to his clients while aligning with GDPR. Find out in this next video about the three things his company does to ensure success.
The original article was published on Bizcast.
Featured News
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany,…